



General description

Cyclophosphamide is an antineoplastic alkylating agent, used in the treatment of many cancers.

INN	Cyclophosphamide
ATC codes	L01AA01
Medicine type	Chemical agent
EML status history	<p>First added in 1977 (TRS 615) for Diffuse large B-cell lymphomas</p> <p>Added in 1977 (TRS 615) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma</p> <p>Added in 1977 (TRS 615) for Rhabdomyosarcoma primary site</p> <p>Added in 1977 (TRS 615) for Hodgkin lymphoma</p> <p>Added in 1977 (TRS 615) for Other specified malignant neoplasms of breast</p> <p>Added in 1977 (TRS 615) for Malignant neoplasms of breast</p> <p>Added in 1977 (TRS 615) for Follicular lymphoma</p> <p>Added in 1977 (TRS 615) for Malignant trophoblastic neoplasms of placenta</p> <p>Added in 1977 (TRS 615) for Burkitt lymphoma including Burkitt leukaemia</p> <p>Added in 1977 (TRS 615) for Lymphoid leukaemia, not elsewhere classified</p> <p>Added in 1977 (TRS 615) for Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2019 (TRS 1021) for Plasma cell myeloma</p> <p>Added in 2021 (TRS 1035) for Other specified gliomas of brain</p> <p>Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis</p>
Wikipedia	Cyclophosphamide ↗
DrugBank	Cyclophosphamide ↗

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid: 25 mg tablet; 50 mg tablet

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Indications

Diffuse large B-cell lymphomas

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Other specified malignant neoplasms of breast

Hodgkin lymphoma

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Other specified gliomas of brain

Malignant neoplasms of kidney, except renal pelvis

